This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

### Populations

Individuals:
- With exposure to medications or radiation that could result in cardiotoxicity

### Interventions

Interventions of interest are:
- Myocardial strain imaging

### Comparators

Comparators of interest are:
- Left ventricular ejection fraction

### Outcomes

Relevant outcomes include:
- Symptoms
- Morbid events
- Quality of life
- Treatment-related mortality
- Treatment-related morbidity

**DESCRIPTION**

Myocardial strain refers to the deformation (shortening, lengthening, or thickening) of the myocardium through the cardiac cycle. Myocardial strain can be measured by tissue Doppler imaging or, more recently, speckle-tracking echocardiography. Speckle-tracking echocardiography uses imaging software to assess the movement of specific markers in the myocardium that are detected in standard echocardiograms. It is proposed that a reduction in myocardial strain may indicate sub-clinical impairment of the heart and can be used to inform treatment before development of symptoms and irreversible myocardial dysfunction.

**SUMMARY OF EVIDENCE**

For individuals who have exposure to medications or radiation that could result in cardiotoxicity who receive myocardial strain imaging, the evidence includes a systematic review of observational studies. Relevant outcomes include symptoms, morbid events, quality of life, treatment-related mortality, and treatment-related morbidity. A systematic review of 13 studies with 384 patients treated for cancer suggests that myocardial strain imaging with tissue Doppler imaging or speckle-tracking echocardiography may be able to identify changes in myocardial deformation that precede changes in left ventricle ejection fraction. Although myocardial strain imaging may detect sub-clinical myocardial changes, the value of these changes in predicting clinical outcomes or guiding therapy is uncertain. No studies were identified that compared the diagnostic accuracy of myocardial strain imaging to left ventricle ejection fraction. A study that will compare clinical outcomes when therapy is guided by myocardial strain imaging or left ventricle ejection fraction is in progress and will provide direct evidence on the clinical utility of myocardial strain imaging. The evidence is insufficient to determine the effects of the technology on health outcomes.
POLICY

Myocardial strain imaging in individuals who have exposure to medications or radiation that could result in cardiotoxicity is investigational.

Myocardial strain imaging is investigational in all other situations.

BACKGROUND

The term strain indicates dimensional or deformational change under force. When used in echocardiography, the term ‘strain’ is used to describe the magnitude of shortening, thickening, and lengthening of the myocardium through the cardiac cycle. The most frequent measure of myocardial strain is the deformation of the left ventricle in the long axis, termed global longitudinal strain. During systole, ventricular myocardial fibers shorten with movement from the base to the apex. Global longitudinal strain is used as a measure of global left ventricle function and provides a quantitative myocardial deformation analysis of each left ventricle segment. Myocardial strain imaging is intended to detect subclinical changes in left ventricle function in patients with a preserved left ventricle ejection fraction, allowing for early detection of systolic dysfunction. Since strain imaging can identify left ventricle dysfunction earlier than standard methods, this raises the possibility of heart failure prophylaxis and primary prevention before the patient develops symptoms and irreversible myocardial dysfunction. Potential applications of speckle-tracking echocardiography are coronary artery disease, ischemic cardiomyopathy, valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathies, stress cardiomyopathy, and chemotherapy-related cardiotoxicity.

MYOCARDIAL STRAIN IMAGING

Myocardial strain can be measured by cardiac magnetic resonance imaging (MRI), tissue Doppler imaging or by speckle-tracking echocardiography. Tissue Doppler strain imaging has been in use since the 1990s but has limitations that include angle dependency and significant noise. In 2016, Smiseth et al reported that the most widely used method of measuring myocardial strain at the present time is speckle-tracking echocardiography. In speckle-tracking echocardiography, natural acoustic markers generated by the interaction between the ultrasound beam and myocardial fibers form interference patterns (speckles). These markers are stable, and speckle-tracking echocardiography analyzes the spatial dislocation (tracking) of each point (speckle) on routine two-dimensional sonograms. Echocardiograms are processed using specific acoustic-tracking software on dedicated workstations, with offline semiautomated analysis of myocardial strain. The two-dimensional displacement is identified by a search with image processing algorithms for similar patterns across two frames. When tracked frame-to-frame, the spatiotemporal displacement of the speckles provides information about myocardial deformation across the cardiac cycle. Global longitudinal strain provides a quantitative analysis of each left ventricle segment, which is expressed as a percentage. In addition to global longitudinal strain, speckle-tracking echocardiography allows evaluation of left ventricle rotational and torsional dynamics.

REGULATORY STATUS

A number of image analysis systems have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Examples of these are shown in Table 1. For example, the Echolnsight software system (Epsilon Imaging) “enables the production and visualization of 2-dimensional tissue motion measurements (including tissue velocities, strains, strain rates) and cardiac structural measurement information derived from tracking speckle in tissue regions visualized in any B mode (including harmonic) imagery loops as captured by most commercial ultrasound systems” (K110447). The FDA determined that this device was substantially equivalent to existing devices (e.g., Syngo US Workplace, Siemens, K091286) for analysis of ultrasound imaging of the human heart.
Table 1. Examples of Software That Have Received FDA Clearance

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Manufacturer</th>
<th>510(k) Number</th>
<th>FDA Product Code</th>
<th>Clearance Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myostrain</td>
<td>Myocardial Solutions</td>
<td>K182756</td>
<td>LNH</td>
<td>02/14/2019</td>
</tr>
<tr>
<td>2D CARDIAC PERFORMANCE ANALYSIS</td>
<td>Tomtec</td>
<td>K120135</td>
<td>LLZ</td>
<td>04/13/2012</td>
</tr>
<tr>
<td>Echolnsight</td>
<td>Epsilon Imaging</td>
<td>K110447</td>
<td>LLZ</td>
<td>05/27/2011</td>
</tr>
<tr>
<td>Q-lab</td>
<td>Phillips</td>
<td>K023877</td>
<td>LLZ</td>
<td>12/23/2002</td>
</tr>
<tr>
<td>Vivid</td>
<td>GE</td>
<td>K181685</td>
<td>IYN</td>
<td>10/25/2018</td>
</tr>
<tr>
<td>Aplio</td>
<td>Toshiba</td>
<td></td>
<td>IYN</td>
<td>01/11/2018</td>
</tr>
</tbody>
</table>

FDA: U.S. Food and Drug Administration.

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

5. Thavendiranathan, PP, Poulin, FF, Lim, KK, Plana, JJ, Woo, AA, Marwick, TT. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol., 2014 Apr 8;63(25 Pt A). PMID 24703918
